Company revenues are primarily generated through the sale of single-use products used during each treatment procedure. Long-term, revenues will also come from sales of TRANBERG® | Mobile Laser Units and technical service. The price for the single-use products is coupled to the health economic value of the treatment which is considered to be significant, and the single-use products are therefore positioned as premium products, offering substantial benefit to healthcare providers in the treatment of tumors. CLS target customers are hospitals and specialist clinics involved in treatment of cancer.
In the US the evaluation of CLS products for MRI-guided laser ablation was initiated in the beginning of 2017, in cooperation with University of Texas Medical Branch. In May 2017 the first patients were treated, at University of Texas Medical Branch, using the equipment.
In Europe CLS focuses a large part of its efforts on clinical evaluation of CLS treatment method Immune stimulating interstitial laser thermotherapy – imILT®.
The TRANBERG®|Thermal Therapy System has not yet a market clearance for imILT® by the Food and Drug Administration (FDA) in the United States of America (USA)
CLS products are approved and marketed in the US and in Europe. Targeted user groups include medical specialists in surgical oncology and oncologic interventional radiology. The first TRANBERG® | Mobile Laser Units has been bought by a US hospital and the first patients, with early stage prostate tumor disease, have been treated using CLS single-use products.
In Europe CLS has ongoing clinical studies in France, Italy, UK, Germany, Portugal and Sweden for different indications. The company’s first post-market clinical report in Europe shows that the products are safe to use for treatment of solid tumors.